Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
AMD
Pharma
With sales turnaround, Astellas projects big growth for Izervay
After reporting a 15% sequential decline in sales of Izervay in the opening quarter of this year, Astellas has reversed the momentum for its GA drug.
Kevin Dunleavy
Jul 10, 2025 4:30pm
Apellis' Syfovre faces tough road ahead in GA market: analyst
May 14, 2025 11:10am
FDA signs off on Astellas' recently acquired GA drug Izervay
Aug 7, 2023 11:16am
FDA grants priority review to Regeneron's high-dose Eylea filing
Feb 23, 2023 10:05am
Bausch + Lomb kicks off 'What Sight Inspires You' campaign
Feb 13, 2023 7:15am
